NCT04123678

DERM Health Economics Study

Impact of an Artificial Intelligence Platform (DERM) on the Healthcare Resource Utilisation (HRU) Needed to Diagnose Skin Cancer When Used as Part of a United Kingdom-based Teledermatology Service

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 700 (actual)
• Sponsor: Skin Analytics Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

This study aims to provide an initial assessment of the potential impact DERM could have on the number of onward referrals for a face to face dermatologist review and/or biopsy from a teledermatology-based service, and to improve the understanding of the patient pathways that exist.

Detailed description

DERM, an Artificial Intelligence (AI)-based diagnosis support tool, has been shown to be able to accurately identify melanoma, non-melanoma skin cancers (NMSC) and other conditions from historical images of suspicious skin lesions (moles). This study aims to establish whether the use of DERM in the patient pathway could reduce the number of unnecessary referrals to dermatologist review and/or biopsy. Suspicious skin lesions that are due to be photographed for a dermatologist to review, will have two additional photographs taken using a commonly available smart phone camera with and without a specific lens attachment. The images will be analysed by DERM, and the results compared to the clinician's diagnosis (all lesions) and histologically-confirmed diagnosis (any lesion that is biopsied).

Conditions

• Melanoma
• Non-melanoma Skin Cancer

Interventions

Type	Name	Description
DEVICE	Deep Ensemble for the Recognition of Malignancy (DERM)	AI-based decision support tool

Timeline

• Start date: 2020-02-26
• Primary completion: 2021-08-05
• Completion: 2021-08-06
• First posted: 2019-10-11
• Last updated: 2021-08-13

Locations

1 site across 1 country: United Kingdom